A recent study suggests that people who come off blockbuster GLP-1 drugs like Mounjaro or Wegovy can put back on reduced body mass much more quickly than those who halt conventional diet and exercise plans.
Findings released in a prominent medical journal demonstrates that while obese people can lose a large proportion of their body weight while on the medication, the mass returns at an estimated rate of 0.8 kg per month once they quit.
"Users purchasing such treatments must be cognizant of the danger of fast rebound weight gain when the treatment is stopped," cautioned expert Dr. Susan Jebb.
That rate of regain means a reversion to pre-treatment weight within about one and a half years.
Analyzing Approaches
The study, which looked at dozens of trials involving thousands of participants, compared the effects of these new drugs with other pills.
Researchers note that individuals who lose weight through diet and exercise typically experience a slower creep back—around 0.1 kg a month—after stopping.
Explaining the Quick Regain
Doctors suggest the mode of action of the injections explains the amplified weight return.
These medications copy a natural hormone called glucagon-like peptide-1, which controls hunger.
"Long-term administration of GLP-1 levels several times higher than normal may cause the body to generate a reduced amount of its own natural hormone, and could lessen responsiveness to its effects," explained Dr. Adam Collins, a nutrition researcher.
"Withdrawal of this hormone supplement results in appetite is uncontrolled, making overeating much more probable."
A Lifelong Condition?
Medical guidelines advise the jabs for individuals with weight-linked health risks, accompanied by recommended lifestyle changes.
Professionals argue that, due to the high risk of relapse, the therapy is often ongoing.
This perspective is echoed by pharmaceutical companies, who note that the results "underscore the chronic nature of obesity," similar to managing diseases like diabetes.
User Accounts
Users who have come off the medication describe a intense resurgence of hunger.
"It was like a trigger that goes on and I was suddenly ravenous," said one woman.
The struggle is exacerbated if patients have not adopted sustainable dietary or behavioural modifications during therapy.
Growing Interest
Survey data suggest that a significant number of people in the UK have used these injections in the last 12 months, with demand being substantial.
- Use is greater among females compared to men.
- The middle-aged demographic shows the highest level of interest.
- Many obtain the drugs through private prescriptions rather than the NHS.
Finally, clinicians emphasize that while these medications are potent agents for shedding pounds, they are not a magic cure and long-term success relies on ongoing lifestyle management.